Qlife advances exclusive commercial agreement with Hipro Biotechnology for Egoo diagnostic platform expansion

PUBT · 1d ago
Qlife advances exclusive commercial agreement with Hipro Biotechnology for Egoo diagnostic platform expansion
  • Qlife advanced an exclusive commercial agreement with Hipro Biotechnology, signed in December 2025, to expand the Egoo diagnostic platform.
  • Qlife and Hipro progressed validation of three assays under a non-binding LOI disclosed on Jan. 28, 2025, targeting heart failure and kidney failure.
  • A feasibility project with a global pharmaceutical company stayed on track, with a broader collaboration agreement expected once deliveries are completed after the summer.
  • Talks opened with another pharmaceutical company on a metabolic-health biomarker “health score” application for Egoo, spanning weight management and healthy ageing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202607170230BITN____UKPR__EN_20260716-BIT-9806-0) on July 17, 2026, and is solely responsible for the information contained therein.